Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 380405, 6 pages
http://dx.doi.org/10.1155/2014/380405
Research Article

Expression of TNF-α, April and BCMA in Behcet’s Disease

1Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Giza, Egypt
2Department of Dermatology, Faculty of Medicine, Cairo University, Giza, Egypt
3Department of Internal Medicine, Kasr Al-Aini Hospital, Faculty of Medicine, Cairo University, Giza, Egypt

Received 26 June 2014; Revised 8 September 2014; Accepted 8 September 2014; Published 5 November 2014

Academic Editor: Clelia M. Riera

Copyright © 2014 Olfat G. Shaker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Hamzaoui, H. Chelbi, F. H. Sassi, and K. Hamzaoui, “Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement,” Oxidative Medicine and Cellular Longevity, vol. 3, no. 2, pp. 122–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Bonyadi, Z. Jahanafrooz, M. Esmaeili et al., “TNF-α gene polymorphisms in Iranian Azeri Turkish patients with Behcet's Disease,” Rheumatology International, vol. 30, no. 2, pp. 285–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Takeno, Y. Shimoyama, and N. Suzuki, “Prolonged survival of autoprimed neutrophils from patients with Behçet's disease (L15),” in Proceedings of the 8th International Congress on Behçet’s Disease, Program and Abstracts 57, Reggio Emilia, Italy, 1998.
  4. B. Turan, K. Pfister, P.-A. Diener et al., “Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease,” Scandinavian Journal of Rheumatology, vol. 37, no. 2, pp. 135–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Yu, T. Boone, J. Delaney et al., “APRIL and TALL-I and receptor BCMA and TACI: system for regulating humoral immunity,” Nature Immunology, vol. 1, no. 3, pp. 252–256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Kayagaki, M. Yan, D. Seshasayee et al., “BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2,” Immunity, vol. 17, no. 4, pp. 515–524, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. F. MacKay and P. Schneider, “Cracking the BAFF code,” Nature Reviews Immunology, vol. 9, no. 7, pp. 491–502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. International Study Group for Behcet's Disease, “Criteria for diagnosis of Behcet's disease,” The Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990. View at Google Scholar
  9. L. I. Kump, K. L. Moeller, G. F. Reed, S. K. Kurup, R. B. Nussenblatt, and G. A. Levy-Clarke, “Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute,” Canadian Journal of Ophthalmology, vol. 43, no. 4, pp. 468–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. B. Bhakta, P. Brennan, T. E. James, M. A. Chamberlain, B. A. Noble, and A. J. Silman, “Behcet's disease: evaluation of a new instrument to measure clinical activity,” Rheumatology, vol. 38, no. 8, pp. 728–733, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Evereklioglu, “Current concepts in the etiology and treatment of Behçet disease,” Survey of Ophthalmology, vol. 50, no. 4, pp. 297–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Kaneko, A. Togashi, S. Saito et al., “Behçet's disease,” Clinical and Developmental Immunology, vol. 2011, Article ID 681956, 7 pages, 2011. View at Publisher · View at Google Scholar
  13. N. Akdeniz, M. Esrefoglu, M. S. Keleş, A. Karakuzu, and M. Atasoy, “Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease,” Annals of the Academy of Medicine Singapore, vol. 33, no. 5, pp. 596–599, 2004. View at Google Scholar · View at Scopus
  14. C. Evereklioglu, H. Er, Y. Türköz, and M. Çekmen, “Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease,” Mediators of Inflammation, vol. 11, no. 2, pp. 87–93, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Sayinalp, O. I. Ozcebe, O. Ozdemir, I. C. Haznedaroğlu, S. Dündar, and S. Kirazli, “Cytokines in Behcet’s disease,” The Journal of Rheumatology, vol. 23, no. 2, pp. 321–322, 1996. View at Google Scholar
  16. K. Hamzaoui, H. Houman, F. Hentati, and A. Hamzaoui, “BAFF is up-regulated in central nervous system of neuro-Behçet's disease,” Journal of Neuroimmunology, vol. 200, no. 1-2, pp. 111–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. P. K. Durmazlar, A. Akgul, and F. Eskioglu, “Homocysteine may involve in the pathogenesis of Behcet's disease by inducing inflammation,” Mediators of Inflammation, vol. 2008, Article ID 407972, 9 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. U. Muftuoglu, H. Yazici, and S. Yurdakul, “Behcet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity,” International Journal of Dermatology, vol. 25, no. 4, pp. 235–239, 1986. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Taysi, R. A. Sari, H. Dursun et al., “Evaluation of nitric oxide synthase activity, nitric oxide, and homocysteine levels in patients with active Behcet's disease,” Clinical Rheumatology, vol. 27, no. 12, pp. 1529–1534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Seyahi, I. Fresko, M. Melikoglu, and H. Yazici, “The management of Behçet's syndrome,” Acta Reumatológica Portuguesa, vol. 31, no. 2, pp. 125–131, 2006. View at Google Scholar · View at Scopus
  21. C. H. Suh, Y. B. Park, J. Song, C. H. Lee, and S. K. Lee, “Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet's disease,” Arthritis & Rheumatology, vol. 44, no. 7, pp. 1707–1712, 2001. View at Google Scholar
  22. J. Freysdottir, S.-H. Lau, and F. Fortune, “γδ T cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS),” Clinical and Experimental Immunology, vol. 118, no. 3, pp. 451–457, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Zierhut, N. Mizuki, S. Ohno et al., “Immunology and functional genomics of Behçet's disease,” Cellular and Molecular Life Sciences, vol. 60, no. 9, pp. 1903–1922, 2003. View at Google Scholar
  24. M. Takeno, A. Kariyone, N. Yamashita et al., “Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice,” Arthritis and Rheumatism, vol. 38, no. 3, pp. 426–433, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. V.-I. Alexaki, V. Pelekanou, G. Notas et al., “B-Cell Maturation Antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies,” Endocrinology, vol. 153, no. 2, pp. 739–749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kawakami, S. Ohashi, Y. Kawa et al., “Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behçet disease: implication in neutrophil apoptosis dysfunction,” Archives of Dermatology, vol. 140, no. 5, pp. 570–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Sun, Y.-P. Wang, J.-S. Chia, B.-Y. Liu, and C.-P. Chiang, “Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-α level in patients with mucocutaneous type of Behcet's disease,” Journal of Oral Pathology and Medicine, vol. 38, no. 5, pp. 401–405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ramanujam, X. Wang, W. Huang et al., “Similarities and differences between selective and nonselective BAFF blockade in murine SLE,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 724–734, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. A. F. de Vos, M. A. C. van Haren, C. Verhagen, R. Hoekzema, and A. Kijlstra, “Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat,” Investigative Ophthalmology and Visual Science, vol. 35, no. 3, pp. 1100–1106, 1994. View at Google Scholar · View at Scopus
  30. M. Santos Lacomba, C. Marcos Martín, J. M. Gallardo Galera et al., “Aqueous humor and serum tumor necrosis factor-α in clinical uveitis,” Ophthalmic Research, vol. 33, no. 5, pp. 251–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Bozoglu, A. Dinc, H. Erdem, S. Pay, I. Simsek, and I. H. Kocar, “Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis,” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. S42–S48, 2005. View at Google Scholar · View at Scopus